(Levonorgestrel and Ethinyl Estradiol tablets USP, 0.15 mg/0.03mg)
Chateal is approved by the FDA as a generic equivalent to Nordette®, and compares to Levora®, Portia®, Altavera®, Marlissa®, and Kurvelo®.
This Afaxys product is indicated for the prevention of pregnancy in women who elect to use an oral contraceptive for contraception.
Facilities that are eligible to become Afaxys Pharmaceuticals dispensers include: Family Planning Centers, Colleges and Universities, Reproductive Health Centers, Community Health Centers, City, County, and State Facilities, and Federal and Government Agencies in the United States.
CHATEAL® IMPORTANT SAFETY INFORMATION
Patients should be counseled that these products do not protect against HIV infection (AIDS) and other sexually transmitted diseases.
Contraindications to CHATEAL include current or past history of thrombophlebitis or thromboembolic disorders, cerebral-vascular or coronary disease, thrombogenic valvulopathies or rhythm disorders, diabetes with vascular involvement, uncontrolled hypertension, known or suspected carcinoma of the breast, carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, cholestatic jaundice of pregnancy or jaundice with prior pill use, hepatic adenomas or carcinomas or active liver disease as long as liver function has not returned to normal, known or suspected pregnancy and hypersensitivity to any components of CHATEAL (levonorgestrel and ethinyl estradiol tablets, USP).
Warnings include thromboembolic disorders and other vascular problems (myocardial infarction, thromboembolism, cerebrovascular disease, dose related risk of vascular disease, persistence of risk of vascular disease), carcinoma of the reproductive organs, hepatic neoplasia, ocular lesions (retinal thrombosis), oral contraceptive use before or during pregnancy, gall bladder disease, carbohydrate and lipid metabolic effects, hypertension, headache and bleeding irregularities.